CAS 1228105-51-8

Maytansine, N2'-deacetyl-N2'-[3-[[1-[[4-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]-

CAS : 1228105-51-8

Formule : C₅₁H₆₆ClN₅O₁₆S

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 1072.6116

Ref: IN-DA000JIN

SMCC-DM1

CAS : 1228105-51-8

SMCC-DM1

Degré de pureté : ≥95%

Masse moléculaire : 1072.61g/mol

Ref: 54-BUP05300

Maytansine Impurity 3 (SMCC-DM1)

CAS : 1228105-51-8

Formule : C₅₁H₆₆ClN₅O₁₆S

Masse moléculaire : 1072.62

Ref: 4Z-M-116034

SMCC-DM1

CAS : 1228105-51-8

SMCC-DM1 is a drug-coupler coupler consisting of a potent microtubule disrupter, DM1, and a coupler, SMCC, for the preparation of antibody-drug couplers.Cost-effective and quality-assured.

Formule : C₅₁H₆₆ClN₅O₁₆S

Degré de pureté : 97.07% - 99.25%

Couleur et forme : Solid

Masse moléculaire : 1072.61

Ref: TM-T16899

SMCC-DM1

Produit contrôlé

CAS : 1228105-51-8

Formule : C₂₆H₂₈O₁₃

Couleur et forme : Neat

Masse moléculaire : 548.493

Ref: TR-S565005

SMCC-DM1

CAS : 1228105-51-8

SMCC-DM1 is a cytotoxic drug conjugate component, which is a chemical compound derived from maytansine, a natural product isolated from the Ethiopian shrub *Maytenus serrata*. It primarily acts as a microtubule inhibitor by binding to tubulin, thereby disrupting the microtubule network within the cell, which results in cell cycle arrest and apoptosis.

This compound is particularly valuable in the field of targeted cancer therapy. In antibody-drug conjugates (ADCs), SMCC-DM1 serves as a payload linked to a monoclonal antibody specific to a tumor antigen. Upon binding to its target antigen on the cancer cell surface, the ADC is internalized and the cytotoxic agent is released, leading to selective destruction of cancerous cells while sparing healthy tissue. This targeted approach enhances therapeutic efficacy and minimizes systemic toxicity.

SMCC-DM1's robust mechanism of action and integration into ADCs make it a pivotal tool for researchers developing next-generation oncological treatments, offering significant potential in translating preclinical findings into clinical applications.

Formule : C₅₁H₆₆ClN₅O₁₆S

Degré de pureté : Min. 95%

Couleur et forme : Powder

Masse moléculaire : 1,072.61 g/mol

Ref: 3D-DZB10551